AI Screening for Diabetic Retinopathy

* WISKY: AI-Powered Retinal Disease Diagnostic Solution WISKY is an advanced solution that performs real-time analysis of images captured by fundus cameras to detect age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. It serves as a vital tool for internal medicine clinics, family medicine practices, and health screening centers, assisting in the early detection, prevention, and management of the three leading causes of blindness.

Aireen’s core product is a fully autonomous diagnostic platform that uses a cascade of neural networks to analyse retina images and identify markers of chronic diseases, delivering results within seconds. The technology is trained on over a million annotated fundus images to ensure high-quality, reliable screening while guarding against operator error, such as poor image quality, and is camera-agnostic to integrate with a wide range of fundus imaging devices. The platform currently supports detection of diabetic retinopathy and age related macular degeneration, with ongoing development aimed at extending capabilities to cardiovascular and neurodegenerative disease screening. Aireen is offered as a cloud-based service with a pay-as-you-go model, helping healthcare providers save time and costs while enabling early detection and intervention. The company has one trademark.

Integrated AI platform for early detection and personalized risk assessment of cardiometabolic diseases through retinal imaging analysis. Designed for seamless integration into hospital and clinic information systems globally.